- ISIN
- US47103J1051
- CUSIP
- 47103J105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 11, 2021
Highlights
- Market Cap
- $925.13M
- Enterprise Value
- $897.35M
- EPS (TTM)
- -$1.84
- Total Revenue (TTM)
- $21.61M
- Gross Profit (TTM)
- $8.44M
- EBITDA (TTM)
- -$134.03M
- Year Range
- $12.12 - $35.34
- Target Price
- $28.40
- ROA (TTM)
- -11.13%
- ROE (TTM)
- -12.16%
- Avg. Volume (1M)
- 851K
- Avg. Volume Value (1M)
- $13.52M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
JANX Performance Chart
Janux Therapeutics, Inc. (JANX) is up 9.9% since the beginning of the year. At $15 per share, JANX is trading 57.1% below its 52-week high of $35. Investors who bought $1,000 worth of JANX shares 5 years ago would now be looking at an investment worth $468.
Loading charts...
Compare this symbol against anything
Returns By Period
Janux Therapeutics, Inc. (JANX) has returned 9.93% so far this year and -35.61% over the past 12 months.
Janux Therapeutics, Inc.
- 1D
- -2.63%
- 1M
- -2.38%
- 6M
- 10.65%
- YTD
- 9.93%
- 1Y
- -35.61%
- 3Y*
- 4.64%
- 5Y*
- -14.10%
- 10Y*
- —
- ALL TIME*
- -14.54%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
JANX Monthly Returns History
Based on dividend-adjusted daily data since Jun 11, 2021, JANX's average daily return is +0.16%, while the average monthly return is +6.20%. At this rate, an investment would double in approximately 1.0 years.
Historically, 48% of months were positive and 52% were negative. The best month was Feb 2024 with a return of +465.2%, while the worst month was Dec 2025 at -59.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.
On a daily basis, JANX closed higher 48% of trading days. The best single day was Feb 27, 2024 with a return of +229.5%, while the worst single day was Dec 2, 2025 at -53.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.65% | -0.73% | 2.13% | 3.38% | 1.53% | 5.28% | -1.24% | 9.93% | |||||
| 2025 | -18.79% | -24.36% | -17.91% | 22.96% | -28.31% | -2.94% | 3.96% | -5.39% | 7.57% | 17.47% | 18.74% | -59.52% | -74.22% |
| 2024 | -20.22% | 465.19% | -22.18% | 51.39% | -6.14% | -21.70% | -3.08% | 15.71% | -3.30% | 18.84% | -16.26% | 18.43% | 398.97% |
| 2023 | 68.64% | -25.12% | -27.24% | 26.61% | -24.15% | 2.15% | 17.94% | -21.43% | -8.36% | -36.31% | 35.98% | 22.91% | -18.53% |
| 2022 | -22.81% | 13.46% | -17.01% | -31.38% | 13.11% | 9.70% | 1.72% | -12.88% | 25.14% | 33.53% | -24.56% | -3.45% | -33.25% |
| 2021 | -26.62% | 29.98% | 5.15% | -36.57% | 12.58% | -26.98% | 10.97% | -41.97% |
Benchmark Metrics
Janux Therapeutics, Inc. has an annualized alpha of 23.78%, beta of 1.48, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since June 11, 2021.
- This stock participated in 204.29% of S&P 500 Index downside but only 128.93% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 23.78%
- Beta
- 1.48
- R²
- 0.04
- Upside Capture
- 128.93%
- Downside Capture
- 204.29%
Return for Risk
Risk / Return Rank
JANX ranks 26 for risk / return — above 26% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Janux Therapeutics, Inc. (JANX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| JANX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.92 | ||
| Sortino ratioReturn per unit of downside risk | -2.14 | ||
| Omega ratioGain probability vs. loss probability | 0.97 | 1.25 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | -0.57 | 2.00 | -2.57 |
| Martin ratioReturn relative to average drawdown | -0.77 | 8.49 | -9.27 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Janux Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Janux Therapeutics, Inc. was 83.14%, occurring on Nov 9, 2023. Recovery took 73 trading sessions.
The current Janux Therapeutics, Inc. drawdown is 77.30%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-83.14%Nov 2023 | 2y 3mo | 3mo 20d | 2y 6moAug 2021 - Feb 2024 | — |
-81.78%Feb 2026 | 1y 2mo | — | 1y 8moDec 2024 - now | — |
-45.52%Aug 2024 | 3mo 3d | 3mo 29d | 7mo 2dMay 2024 - Dec 2024 | — |
-45.35%Jun 2021 | 4d | 1mo 18d | 1mo 22dJun 2021 - Aug 2021 | — |
-29.41%Apr 2024 | 1mo 7d | 6d | 1mo 13dFeb 2024 - Apr 2024 | — |
Drawdown Indicators
| JANX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.14% | -56.78% | -26.36% |
Max Drawdown (1Y)Largest decline over 1 year | -64.94% | -9.10% | -55.84% |
Max Drawdown (3Y)Largest decline over 3 years | -81.78% | -18.90% | -62.88% |
Max Drawdown (5Y)Largest decline over 5 years | -83.14% | -25.43% | -57.71% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -77.30% | -1.58% | -75.72% |
Average DrawdownAverage peak-to-trough decline | -53.27% | -10.70% | -42.57% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 47.65% | 2.14% | +45.51% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Janux Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Janux Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for JANX relative to other companies in the Biotechnology industry. Currently, JANX has a P/S ratio of 43.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for JANX in comparison with other companies in the Biotechnology industry. Currently, JANX has a P/B value of 1.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with JANX
Add Janux Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with JANX